Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: John McCarthy who wrote (11430)	11/19/1997 12:44:00 AM
From: Andrew H	Read Replies (2) \| Respond to of 32384

>>I am trying to voice the thought that , to some degree, if you do diabetes , your a little bit dangerous.<< Possible that some in the market think this way. However, LLY just took away almost all of the risk you talk about. If pramlintide fails, AMLN is completely washed up, not to mention that they have paid a good portion of the trials and development costs. If Targretin for diabetes fails, LGND loses nothing but royalties they may never see anyway. My guess is that its not a big uncertainty for the market in regard to LGND's price, especially since they have so many drugs in their pipeline and LLY is bearing all the costs.